Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 1/20 | 1.00 |
| ▸ | PARP1 | P09874 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478301 | 1.00 | TRPM2 (1.00) | TRPM2PARP1HRH3ALDH1A1KDM4E | |
| SCHEMBL7587804 | 0.96 | TRPM2 (0.93) | TRPM2PARP1HRH3ALDH1A1KDM4E | |
| SCHEMBL5074084 | 0.94 | PARP1 (0.89) | TRPM2PARP1HRH3ALDH1A1KDM4E | |
| SCHEMBL7583074 | 0.93 | PARP1 (0.87) | TRPM2PARP1HRH3ALDH1A1KDM4E | |
| SCHEMBL9196870 | 0.80 | PARP1 (0.66) | TRPM2PARP1 | |
| SCHEMBL5076323 | 0.80 | PARP1 (0.66) | TRPM2PARP1ALDH1A1KDM4EKMT2A | |
| SCHEMBL7586205 | 0.79 | PARP1 (0.65) | TRPM2PARP1HTR2ACYP1A2CYP2C19 | |
| SCHEMBL4717294 | 0.79 | PARP1 (0.65) | TRPM2PARP1 | |
| SCHEMBL7583746 | 0.79 | ABCB1 (0.74) | TRPM2PARP1CYP2D6CYP2C19 | |
| SCHEMBL9447382 | 0.79 | ABCB1 (0.74) | TRPM2PARP1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230383363-A1 | METHOD FOR DETERMINING SENSITIVITY TO PARP INHIBITOR OR DNA DAMAGING AGENT USING NON-FUNCTIONAL TRANSCRIPTOME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-11-30 | — | — | US | claimed |
| EP-4243023-A1 | METHOD FOR DETERMINING SENSITIVITY TO PARP INHIBITOR OR DNA DAMAGING AGENT USING NON-FUNCTIONAL TRANSCRIPTOME | Korea Advanced Institute of Science and Technology (KR) | 2023-09-13 | — | — | EP | claimed |
| WO-2022098086-A1 | METHOD FOR DETERMINING SENSITIVITY TO PARP INHIBITOR OR DNA DAMAGING AGENT USING NON-FUNCTIONAL TRANSCRIPTOME | 한국과학기술원 | 2022-05-12 | — | — | WO | claimed |
| WO-2021086107-A1 | METHOD FOR DETERMINING REACTIVITY TO PARP INHIBITOR | (재)록원바이오융합연구재단 | 2021-05-06 | — | — | WO | claimed |
| US-10159685-B2 | Vascular calcification | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2018-12-25 | — | — | US | claimed |
| US-20170360809-A1 | VASCULAR CALCIFICATION | KING'S COLLEGE LONDON (GB) | 2017-12-21 | — | — | US | claimed |
| US-20060094676-A1 | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2006-05-04 | — | — | US | claimed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | claimed |
| US-RE50319-E1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3697767-B1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230383363-A1 | METHOD FOR DETERMINING SENSITIVITY TO PARP INHIBITOR OR DNA DAMAGING AGENT USING NON-FUNCTIONAL TRANSCRIPTOME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-11-30 | — | — | US | disclosed |
| WO-1999011649-A2 | PARP INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS OF USING SAME | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1999011644-A1 | DI-N-HETEROCYCLIC COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHIBITING PARP ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1999008680-A1 | METHOD OF USING SELECTIVE PARP INHIBITORS TO PREVENT OR TREAT NEUROTOXICITY | THE JOHNS HOPKINS UNIVERSITY (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360809-A1 | VASCULAR CALCIFICATION | PARP1, PARP2, PARP11 | TRPM2 2977/4885PARP1 1/4885HRH3 3800/4885 |
| US-10159685-B2 | Vascular calcification | PARP1, PARP2, PARP11 | TRPM2 2977/4885PARP1 1/4885HRH3 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.